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Primary extra-nodal non-Hodgkin’s lymphomas (NHL) constitute 25–40% of NHL but less than 1% arises in oral cavity. Here in 53-year-old 
man with stage IE gingival diffuse large B cell lymphoma who was treated successfully with chemotherapy and radiotherapy was presented.
Key Words: gingival lymphoma, primary extra-nodal non-Hodgkin’s lymphomas. 
Non-Hodgkin’s lymphomas (NHLs) are hetero-
geneous disease and diffuse large B cell lymphoma 
(DLBCL) is the most common type which represents 
about 30% of all NHL [1, 2]. DLBCL is an aggressive 
lymphoma and like most NHLs, there is a male pre-
dominance. Although the most NHLs arise in lymph 
nodes, 25–40% of patients with NHL present with extra 
nodal involvement. Whereas the definition of primary 
extra-nodal NHL (PE-NHL is a controversial issue, 
especially in patients with both nodal and extra nodal 
sites involvement. The incidence of PE-NHL is increas-
ing worldwide [2–5]. Although NHLs can involve any 
organ and tissue, the most of PE-NHL arise from gas-
trointestinal tractus but in less than 1% of the patients 
the initial sites may be in oral cavity [3–6].
Patients with DLBCL typically present with a pro-
gressive enlargement of a mass, most usually lymph 
node enlargement in the neck or abdomen. “B” 
symptoms (i.e., fever, weight loss, night sweats) 
are observed in approximately 30% of patients, 
and the serum LDH is elevated in over one-half [3]. 
In the extra-nodal disease, patients present with the 
concerned organ’s symptoms. As it can be difficult 
to diagnose and diffuse B cell lymphoma is aggres-
sive in the atypical presentation the lymphomas have 
to be kept in mind. A combination of chemotherapies 
and the monoclonal antibody rituximab (R) can lead 
to a cure in a large number of people with this form 
of lymphoma. The most common regime is R-CHOP 
or CHOP for 6–8 cycles. Patients in early stages also 
benefit from radiation to involved areas [3, 6].
The purpose of this report is to demonstrate a case 
of extra-nodal DLBCL arising on the gingiva and to em-
phasize the difficulty of the diagnosis of the gingival 
disease not improved with routine dental treatment.
A 53-year-old man was admitted to our clinic with 
3 months complaint of teeth and gingival pain at Decem-
ber 2010. His teeth were pulled out after a course of an-
tibiotic therapy but his complaints got worsened (Fig. 1).
Fig. 1. Pretreatment gingival appearance of patient
A gingival biopsy from the left premolar side was 
done by his dentist. The histological examination of the 
biopsy revealed that a tumoral infiltration consisting 
of cells with large nucleus, prominent nucleolus and 
insignificant cytoplasm (Fig. 2 and 3).
Fig. 2. Oral submucosal tissue completeley filled with tumoral 
mass (Hematoxylin&Eosin x40)  
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Fig. 3. Sheet-like tumoral mass was composed of large cells 
with pale nuclei. Number of atypical mitotic figures were seen 
(arrow) (Hematoxylin&Eosin x40)
The immunohistochemical examination showed 
staining of tumor cells with CD45, CD20, and vimentin 
but S100, SMA, and keratin were negative (Fig. 4).
Fig. 4. Tumor cells were diffuse positive with CD20 (DAB x200) (B)
He had a gingival pain, paresthesia at his chin on the 
administration. The physical examination and complete 
blood count, biochemical investigations, and chest x-ray 
were within normal limits. The patient’s beta 2 micro-
globulin level was 2 mg/L (normal range: 0,7–1,8 mg/L) 
and LDH and ESR was in the normal range. In addition, 
lymphoma infiltration was not observed at evaluation 
of bone marrow aspiration and biopsy. The computerized 
tomography (CT) evaluation of neck, thorax, and abdo-
men revealed no abnormality. The patient was treated 
with four cycles of R-CHOP (rituximab 375 mg/m2, 
cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, 
vincristine 1.4 mg/m2 (for a maximal dose of 2 mg), and 
oral prednisone 100 mg/d on days 1–5) chemotherapy 
with a final diagnosis of stage 1E DLBCL. Following 
four cycles of chemotherapy, he was given a total dose 
of 4000 cGy divided into 20×200 cGy fractions to the 
involved field. After 4 cycles of CT and IFRT, complete 
response was achieved and the patient has been fol-
lowed up for 18 months without any evidence of relapse.
PE-NHLs of oral cavity usually presents with an as-
ymptomatic gingival hypertrophy or a mass of tissue 
mimicking common oral and dental pathologic condi-
tions. Therefore, the diagnosis of the lymphoma can 
be delayed. In our case, the patient had gingival pain 
so he had gone to a dentist and had some teeth pulled 
out. Because of the worsening symptoms a gingival 
biopsy was done, which showed the malign infiltration 
and its treatment led to a cure of a malign disease.
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